Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
News Archive
News Archive Navigation
News Archive Navigation Language
September 2024
-
Featured News
Test ARC-43886
Explore opportunities with Novartis below
-
Featured News
Test-Our next era
Novartis poised to expand impact on human health as it begins next era.
Dec 04, 2023It’s a historic moment for Novartis. Following the Sandoz spin-off in October and capping a multi-year transformation, we’ve entered our next era as an innovative medicines company. In this new chapter, our commitment to our purpose of reimagining medicine to improve and extend peoples’ lives remains unwavering.
We’re focusing our energy on disease areas where there is significant need for new treatments and where we have deep expertise and capabilities. We’re also building on our strengths in advanced new technology platforms – radioligand therapy, RNA therapeutics and gene and cell therapy – that will help us deliver the next generation of medicines for patients.
-
Key Release
Test -Featured news
Novartis Financial Results – Q2 2024
Novartis announced the company’s financial results for the second quarter and first half of 2024.
-
Featured News
Featured News
August 2024
January 2024
December 2023
October 2023
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 12
- › Next page
Test disclaimer...!!!